Table 2.

Standard treatment regimens for previously untreated patients

		Duration	Intensive phase	Continuous phase
Method A	Standard	6 months*	RFP+NH+PZA+SM (or EB) for 2 months	RFP+INH for 4 months*,**
Method B	Only when PZA cannot be administered ***	9 months *	RFP+INH+SM (or EB) for 2 months	RFP+INH for 7 months*,**

INH: isoniazid, RFP: rifampicin, PZA: pyrazinamide, EB: ethambutol, SM: streptomycin

*  The treatment period of continuous phase can be prolonged by 3 months for patients with severe lesions or those with diabetes etc, resulting in 9 months for Method A and 12 months for Method B, in total.

** When drug susceptibility is unknown and symptom improvement is unclear, SM (or EB) is continued until drug susceptibility is identified or clinical improvement is confirmed.

*** Method B is used only when pyrazinamide cannot be administered due to adverse reactions for those such as patients with underlying hepatic disorders or elderly patients aged 80 years or older.